JP2020508985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508985A5 JP2020508985A5 JP2019543376A JP2019543376A JP2020508985A5 JP 2020508985 A5 JP2020508985 A5 JP 2020508985A5 JP 2019543376 A JP2019543376 A JP 2019543376A JP 2019543376 A JP2019543376 A JP 2019543376A JP 2020508985 A5 JP2020508985 A5 JP 2020508985A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- dendrimer
- formula
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000412 dendrimer Substances 0.000 claims description 90
- 229920000736 dendritic polymer Polymers 0.000 claims description 90
- 229920001223 polyethylene glycol Polymers 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 28
- 125000003277 amino group Chemical group 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 230000002489 hematologic Effects 0.000 claims 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 208000009721 Leukemia, Monocytic, Acute Diseases 0.000 claims 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 1
- 206010028549 Myeloid leukaemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000389 T-Cell Leukemia Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 1
- 230000001808 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461983P | 2017-02-22 | 2017-02-22 | |
| US62/461,983 | 2017-02-22 | ||
| US201762488151P | 2017-04-21 | 2017-04-21 | |
| US62/488,151 | 2017-04-21 | ||
| US201762591823P | 2017-11-29 | 2017-11-29 | |
| US62/591,823 | 2017-11-29 | ||
| PCT/EP2018/054420 WO2018154004A1 (en) | 2017-02-22 | 2018-02-22 | Therapeutic dendrimers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508985A JP2020508985A (ja) | 2020-03-26 |
| JP2020508985A5 true JP2020508985A5 (ru) | 2021-03-11 |
| JP7074761B2 JP7074761B2 (ja) | 2022-05-24 |
Family
ID=61386833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543376A Active JP7074761B2 (ja) | 2017-02-22 | 2018-02-22 | 治療用デンドリマー |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10314920B2 (ru) |
| EP (1) | EP3585441A1 (ru) |
| JP (1) | JP7074761B2 (ru) |
| KR (2) | KR20230093346A (ru) |
| CN (2) | CN117582521A (ru) |
| AU (1) | AU2018223149B2 (ru) |
| BR (1) | BR112019016409A2 (ru) |
| CA (1) | CA3053069A1 (ru) |
| CL (1) | CL2019002240A1 (ru) |
| CO (1) | CO2019009722A2 (ru) |
| CR (1) | CR20190361A (ru) |
| DO (1) | DOP2019000204A (ru) |
| EC (1) | ECSP19056271A (ru) |
| IL (1) | IL268648B (ru) |
| JO (1) | JOP20190191A1 (ru) |
| MX (1) | MX2019009442A (ru) |
| NI (1) | NI201900088A (ru) |
| PE (1) | PE20191660A1 (ru) |
| PH (1) | PH12019501896A1 (ru) |
| SG (1) | SG11201907334QA (ru) |
| TW (1) | TWI773730B (ru) |
| UA (1) | UA125655C2 (ru) |
| WO (1) | WO2018154004A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| TW202021575A (zh) * | 2018-08-17 | 2020-06-16 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
| SG11202104239XA (en) * | 2018-11-20 | 2021-06-29 | Starpharma Pty Ltd | Therapeutic dendrimer |
| KR20220072851A (ko) * | 2019-09-26 | 2022-06-02 | 스타파마 피티와이 리미티드 | 치료용 덴드리머 |
| EP4069307A2 (en) * | 2019-12-04 | 2022-10-12 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery |
| TW202206106A (zh) * | 2020-04-24 | 2022-02-16 | 大陸商上海森輝醫藥有限公司 | 一類載藥的大分子及其製備方法 |
| CN116075322A (zh) | 2020-04-24 | 2023-05-05 | 阿什瓦塔治疗股份有限公司 | 用于治疗重度急性呼吸窘迫综合征的树枝状大分子组合物和方法 |
| BR112023000320A2 (pt) * | 2020-07-10 | 2023-01-31 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso |
| KR20230057416A (ko) * | 2020-08-25 | 2023-04-28 | 상하이 센후이 메디슨 컴퍼니 리미티드 | 약물 담지 거대분자 및 이의 제조 방법 |
| US20230263900A1 (en) * | 2020-08-31 | 2023-08-24 | Starpharma Pty Ltd. | Dendrimer-drug conjugate |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4289872A (en) * | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US4410688A (en) * | 1981-04-29 | 1983-10-18 | Allied Corporation | Macromolecular highly branched homogeneous compound |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| WO2007040650A2 (en) | 2005-05-12 | 2007-04-12 | Abbott Laboratories | Apoptosis promoters |
| EP1940916B1 (en) * | 2005-10-25 | 2016-12-14 | Starpharma Pty Limited | Macromolecular compounds having controlled stoichiometry |
| WO2007082331A1 (en) * | 2006-01-20 | 2007-07-26 | Starpharma Pty Limited | Modified macromolecule |
| US9127130B2 (en) * | 2006-08-11 | 2015-09-08 | Starpharma Pty Ltd. | Polylysine dendrimer contrast agent |
| EP2052011B1 (en) * | 2006-08-11 | 2020-11-04 | Starpharma Pty Limited | Targeted polylysine dendrimer therapeutic agent |
| EP2094672B1 (en) | 2006-11-15 | 2013-05-29 | Genentech, Inc. | Arylsulfonamide compounds |
| US9283302B2 (en) | 2011-12-16 | 2016-03-15 | Cormatrix Cardiovascular, Inc. | Extracellular matrix encasement structures and methods |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| ES2672526T3 (es) | 2008-06-26 | 2018-06-14 | Prolynx Llc | Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas |
| US8216549B2 (en) * | 2008-07-25 | 2012-07-10 | National Health Research Institutes | Method for making a ligand-quantum dot conjugate |
| EP2376480B1 (en) | 2008-12-05 | 2016-06-01 | AbbVie Inc. | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| KR101920202B1 (ko) | 2009-05-26 | 2018-11-21 | 애브비 아일랜드 언리미티드 컴퍼니 | 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 |
| TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| US20120269721A1 (en) * | 2009-10-12 | 2012-10-25 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| WO2011140376A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
| JP5964815B2 (ja) | 2010-05-05 | 2016-08-03 | プロリンクス リミテッド ライアビリティ カンパニー | 固体担体からの放出制御薬物 |
| US8754190B2 (en) | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| WO2012167309A1 (en) * | 2011-06-06 | 2012-12-13 | Starpharma Pty Ltd | Macromolecules |
| US20160220689A1 (en) * | 2013-09-10 | 2016-08-04 | Starpharma Pty Ltd. | Macromolecules of dendrimer-platinum conjugates |
| US10730999B2 (en) * | 2014-06-06 | 2020-08-04 | Starpharma Pty Ltd | Dendrimer-drug conjugates |
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| TW202021575A (zh) * | 2018-08-17 | 2020-06-16 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
-
2017
- 2017-06-16 JO JOP/2019/0191A patent/JOP20190191A1/ar unknown
-
2018
- 2018-02-12 TW TW107105033A patent/TWI773730B/zh active
- 2018-02-20 US US15/899,892 patent/US10314920B2/en active Active
- 2018-02-22 BR BR112019016409A patent/BR112019016409A2/pt unknown
- 2018-02-22 AU AU2018223149A patent/AU2018223149B2/en active Active
- 2018-02-22 CN CN202311534590.1A patent/CN117582521A/zh active Pending
- 2018-02-22 CN CN201880012429.9A patent/CN110312531A/zh active Pending
- 2018-02-22 EP EP18707681.5A patent/EP3585441A1/en active Pending
- 2018-02-22 KR KR1020237019533A patent/KR20230093346A/ko active IP Right Grant
- 2018-02-22 CA CA3053069A patent/CA3053069A1/en active Pending
- 2018-02-22 JP JP2019543376A patent/JP7074761B2/ja active Active
- 2018-02-22 KR KR1020197027415A patent/KR102544033B1/ko active IP Right Grant
- 2018-02-22 CR CR20190361A patent/CR20190361A/es unknown
- 2018-02-22 PE PE2019001564A patent/PE20191660A1/es unknown
- 2018-02-22 UA UAA201909735A patent/UA125655C2/uk unknown
- 2018-02-22 WO PCT/EP2018/054420 patent/WO2018154004A1/en unknown
- 2018-02-22 MX MX2019009442A patent/MX2019009442A/es unknown
- 2018-02-22 SG SG11201907334QA patent/SG11201907334QA/en unknown
-
2019
- 2019-04-05 US US16/376,419 patent/US10888624B2/en active Active
- 2019-08-06 EC ECSENADI201956271A patent/ECSP19056271A/es unknown
- 2019-08-08 DO DO2019000204A patent/DOP2019000204A/es unknown
- 2019-08-08 CL CL2019002240A patent/CL2019002240A1/es unknown
- 2019-08-12 IL IL268648A patent/IL268648B/en unknown
- 2019-08-15 PH PH12019501896A patent/PH12019501896A1/en unknown
- 2019-08-20 NI NI201900088A patent/NI201900088A/es unknown
- 2019-09-09 CO CONC2019/0009722A patent/CO2019009722A2/es unknown
-
2020
- 2020-11-11 US US17/095,043 patent/US11717574B2/en active Active
-
2023
- 2023-06-14 US US18/334,672 patent/US20240115716A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508985A5 (ru) | ||
| KR100559068B1 (ko) | 캄프토테신 유도체, 이의 중합체성 복합체, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물 | |
| CN102686243B (zh) | 用于抗癌剂递送的聚合物*** | |
| RU2014134409A (ru) | Конъюгаты этопозида и доксорубицина для доставки лекарственных средств | |
| US20200297693A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
| TW200813115A (en) | Polymer conjugate of combretastatin | |
| US20070197427A1 (en) | O,o'-amidomalonate and n,o-amidomalonate platinum complexes | |
| KR20080108592A (ko) | 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물 | |
| CA3025931A1 (en) | Antibody drug conjugates having derivatives of amatoxin as the drug | |
| TW201004647A (en) | Novel dual targeting antitumoural conjugates | |
| JP2012510477A5 (ru) | ||
| JP2008504235A5 (ru) | ||
| US6376617B1 (en) | Bioactive derivatives of camptothecin | |
| FI116058B (fi) | Kolme ydintä käsittävät kationiset platinakompleksit, joilla on kasvaimenvastainen vaikutus, sekä niitä sisältävät farmaseuttiset koostumukset | |
| EP4066860A1 (en) | Polyethylene glycol conjugated drug, and preparation method therefor and use thereof | |
| CA2396702A1 (en) | N,o-amidomalonate platinum complexes | |
| US20160220689A1 (en) | Macromolecules of dendrimer-platinum conjugates | |
| TW201004631A (en) | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof | |
| KR20210034011A (ko) | 치료 덴드리머 | |
| WO2014084378A1 (ja) | 環状ｒｇｄ配列含有ペプチドを含む抗癌剤 | |
| HRP20100301T1 (hr) | Ciklopeptidni derivati sa anti-integrinskom aktivnošću | |
| EP2737896B1 (en) | Umirolimus micelle for the treating cancer | |
| KR102138415B1 (ko) | 신규 peg 유도체 | |
| US20060052288A1 (en) | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | |
| CA3126574C (en) | Cd44 targeted multi-arm conjugate |